Schlieren / Zurich, Switzerland, 4 November, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces today that Frits van Alphen, MD has been appointed as Chief Development Officer (CDO). He succeeds Dr. Gerald P. Parzmair, who stepped down to pursue other opportunities.

Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces today that the last patient has been enrolled in its 22-site U.S. Phase II trial for its BK polyomavirus ("BKV")-neutralizing antibody, potravitug.

DIEPENBEEK, Belgium, LEICESTER, England, and LOS ANGELES, USA (October 28, 2024) – Rejuvenate Biomed, the University of Leicester, the National Institute for Health and Care Research (NIHR), Leicester Biomedical Research Centre (BRC), and Wellcome Leap Inc. announced today that they have entered into an agreement to execute a Phase 2 clinical trial in patients with chronic obstructive pulmonary disease (COPD)-related sarcopenia.

Hamburg, Germany, October 15th, 2024 – Topas Therapeutics today announced positive topline results from its Phase 2a trial evaluating lead candidate, TPM502, in patients with celiac disease. The study data serves as the first clinical proof of concept for Topas' proprietary nanoparticle platform and its potential to induce targeted, antigen-specific tolerogenic effects.

Schlieren / Zurich, Switzerland, 27 August, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique human immune responses into superior medicines to treat viral infections and cancer, today announces that Alex Bastian has joined the Company as VP Commercial Strategy.

Munich, Germany, July 16, 2024 – CatalYm today announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion's Growth Opportunities Fund ("Forbion Growth"), Omega Funds and Gilde Healthcare. Existing investors Jeito Capital, Brandon Capital Partners, Novartis Venture Fund and Vesalius Biocapital III also participated in the round.

Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors.

Munich, Germany, June 2, 2024 – CatalYm today announced positive new follow-up results from its ongoing "GDFATHER" Phase 1/2a trial (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 1/2a) (NCT04725474) in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 in Chicago.

Schlieren / Zurich, Switzerland, 7^th May, 2024 – Memo Therapeutics AG (or "MTx") today announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.

Amsterdam, the Netherlands, April 30, 2024 – Scenic Biotech today announced that it has entered into a research collaboration with Bristol Myers Squibb (NYSE: BMY) to accelerate the development of Bristol Myers Squibb's drug targets by identifying target biology for indication selection and expansion.